What is the shelf life of the product?

The validity period is 24 months.

What are the common adverse reactions?

Adverse reactions may include nausea, vomiting, headache, insomnia, irritability, tachycardia, and hyperglycemia.

Doxofylline Injection, IV Fluid, IV Solution

Name: Doxofylline Injection, IV Fluid, IV Solution
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2002607262

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.43

100,000 ampoules

Sample price:US$0.50/piece.Request sample

Product profile

Customization

Available

Application

Oral Preparation

Usage Mode

Injection

Model NO.

10ml: 0.1g

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Fluid

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

Guoyaozhunzih20203015

Package

50ampoules/Box,18boxes/Carton

Cartons Size

420*325*440mm

Transport Package

Carton

Specification

10ml: 0.1g

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

5000000000

Key features

Indications for Respiratory Conditions: Treats dyspnea caused by bronchial asthma, chronic asthmatic bronchitis, and other bronchospasms.

GMP Certified Manufacturer: Produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd., a global GMP manufacturer.

Long Shelf Life: Valid for 24 months when stored sealed in a dry place.

Clear Liquid Formulation: Colorless clear liquid suitable for intravenous injection.

Flexible Packaging Options: Available in PP ampoules with 50 ampoules per box and 18 boxes per carton.

Global Export Capability: Exporter since 2002 with markets in South America, Southeast Asia, Africa, and more.

Multiple Payment Terms: Accepts T/T and LC for international transactions.

Detailed Dosage Instructions: Adult dosage is 200mg every 12 hours, diluted and infused slowly over 20 minutes.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.